

September 30, 2019

Mr. Daniel Timberlake Director Department of Planning and Budget 1111 East Broad Street, Room 5040 Richmond, Virginia 23219

Dear Mr. Timberlake:

Enclosed please find the fourth Quarterly Report for FY2019 Center for Innovative Technology. The attached report fulfills the requirements of the Code of Virginia, §2.2-2221.1.C (includes reporting requirements of Item 126.10.D.2 of the 2019 Appropriations Act).

Please feel free to call me at 703-689-3021 if you have any questions.

Sincerely,

Susan ath

Susan Aitcheson CFO Center for Innovative Technology

cc: The Honorable Brian Ball, Secretary of Commerce and Trade Mr. Robby Demeria, Deputy Secretary, Commerce and Trade The Honorable Emmett W. Hanger, Jr., Co-Chairman, Senate Finance Committee The Honorable Thomas K. Norment, Jr., Co-Chairman, Senate Finance Committee The Honorable S. Chris Jones, Chairman, House Appropriations Committee Mr. Robert P. Vaughn, Staff Director, House Appropriations Committee Mr. Jason Powell, Staff Co-Director, Senate Finance Committee Ms. April Kees, Staff Co-Director, Senate Finance Committee Ms. Toni Walker, Associate Director, Department of Planning and Budget Ms. Samantha Martin, Budget and Policy Analyst, Department of Planning and Budget Mr. Rob Quartel, CIT Board of Directors Finance Committee Chairman Mr. Bernard Mustafa, CIT Board of Directors Vice Chairman Mr. Michael Steed, CIT Board of Directors Chairman

Center for Innovative Technology 2214 Rock Hill Road Suite 600 Herndon, VA 20170-4228 Tel.703.689.3000 www.cit.org

CENTER FOR INNOVATIVE TECHNOLOGY

And

INNOVATION AND ENTREPRENEURSHIP INVESTMENT AUTHORITY

Financial Performance Reporting

Quarter and Fiscal Year Ended June 30, 2019

Items 126.10.D.2.a-c



CENTER FOR INNOVATIVE TECHNOLOGY

Item 126.10.D.2.a

Fiscal Year 2019 Quarter 4 June 30, 2019

Financial Performance

Commonwealth Project	s Funded by Approp	oriation & Other	Manager and a second se	
	-		(In Thousands)	
	-		TUAL - July 2018 - Ju	
Revenue		Actual	<u>Budget</u>	Variance
Commonwealth Appropriation - General Fund		\$ 10,93	8 \$ 10,272	2 \$ 666
Interest, Sponsorship, Return on Investments & Misc. Incon	ne	2,39		
	Total Revenue	13,33	7 10,343	2 2,995
Program Expenses				
R&D - Commonwealth Research and Technology Strategic		2		5 18
R&D - Commonwealth Research Commercialization Fund Entrepreneur - Federal Proposal Assistance		3,33 26		
Entrepreneur - Growth Acceleration Program		5,58		
Broadband - Office of Telework Promotion		3		
Broadband - Broadband Planning and Assistance		68		
Commonwealth - Regional Growth		18		
Commonwealth - Cyber Commission		53	6 853	3 (317)
Commonwealth - Unmanned Systems		1,03	5 74	5 290
Commonwealth - Unmanned Systems Center of Excellence		45	3 1,919	9 (1,466)
Commonwealth - Building Management	-	1		- 18
	Program Expenses	12,14	9 13,737	7 (1,588)
Other Evenness				
Other Expenses Marketing, Advocacy, Fundraising and Miscellaneous		42	0 357	7 63
Unapplied (over-applied) indirects		(36		
onapplied (over-applied) indirects	Other Expenses	(30	'	
				(200)
	Total Expenses	12,20	3 14,084	4 (1,881)
	-			
	Net_	1,13	4 (3,742	2) 4,876
Strategic Initiat	tives Funded by Con	tracts & Grants	3	
Description DMME Operations with Free Freed				
Program Revenue - DMME Commonwealth Energy Fund		28	2 3 4 400	.,
Program Expense	Profit/(Loss)*	(28)		
*covered by return on investment proceeds re		(20)	(55)	/ 113
Program Revenue - DHS SCIIP		1,85		5 149
Program Expense		1,71		
	Profit/(Loss)	13	9 126	i 13
Commonwealth Project	s Funded by Approp	riation & Other	Revenue	
Program Revenue - UVA Wise Verizon Grant		1	1	- 11
Program Expense		1		- 11
	Profit/(Loss)		-	
	Program Revenue	1,86	7 1,708	3 159
	Program Expenses	2,010	0 1,979) 31
	Net _	(14:	3) (271) 128
Consolidated Revenu	Expanses and Ch	anges in Met D	opition	
Revenue	c, cybenses and Cu	15,204	nor, Andustria and Ar	3,154
Expenses		14,21		
Change in Net Position	·	99		
Beginning Net Position		8,71		
Ending Net Position		\$ 9,702		
	.=			

INNOVATION AND ENTREPRENEURSHIP INVESTMENT AUTHORITY BUDGET ANALYSIS FOR BUILDING OPERATIONS ONLY

For the Fiscal Year Ended June 30, 2019

	In thousands						
BUILDING ANALYSIS		ACTUAL	July	- July 2018 to June 2019			
	A	Actual		Budget		riance	
REVENUE							
Rental Income - lease revenue	\$	868	\$	766	\$	102	
Total Revenue		868		766	U.	102	
BUILDING EXPENSES							
Payroll		250		244		6	
Utilities		351		380		(29	
Administrative		138		132		6	
Operating & Maintenance		49		102		(53	
Contracts		336		382		(46	
Insurance		100		100		-	
Food Service Subsidy		-		42		(42	
Leasing Commission and Miscellaneous		15		15		÷	
Total Expenses		1,239		1,397		(158	
Net Income	\$	(371)	\$	(631)	\$	260	

Item 126.10.D.2.b

Fiscal Year 2019 Quarter 4 June 30, 2019

Investments & Grants

Center for Innovative Technology Investments Made and Return on Prior Investments For the year ended June 30, 2019

Investments made:			
investments made.	Actual	Budget	Variance
Ario Technologies, Inc	50,000.00		
Artglass	50,000.00		
Atomic Corp	104,850.00		
Babylon Micro-Farms Inc	50,000.00		
Churnzero inc	74,518.21		
Couloumb (Lumen)	200,000.00		
Dark3	100,000.00		
Dart Ventures (Drone-Up LLC)	200,000.00		
Divvy Cloud Corporation	250,000.00		
Embody	250,000.00		
Fenris, Inc	125,000.00		
Fourstay, Inc	200,000.00		
FRNGE	50,000.00		
Gathering (Rize)	100,000.00		
Hyperqube (Cyber Acad/Network Systems)	50,000.00		
LiteSheet	100,000.00		
Manor Financial Inc (UpSideDoor)	36,652.50		
Metallum3D Inc	25,000.00		
Micronic Technologies, LLC	50,000.00		
Novi, LLC	50,000.00		
Ostendio, Inc	123,378.90		
Plutus	50,000.00		
Pype	100,000.00 25,000.00		
Quirk Inc Runsafe Security, Inc	100,000.00		
Scenethink	50,000.00		
Sensewear	100,000.00		
Skyphos Industries, Inc	25,000.00		
Societas	50,000.00		
Stratus Digital	50,000.00		
Student Opp	100,000.00		
	50,000.00		
Tympanogen	50,000.00		
	50,000.00	\$ 2,270,000.00	\$ 669,399.61
Tympanogen	50,000.00	\$ 2,270,000.00	\$ 669,399.61
	50,000.00	2,270,000.00	\$ 669,399.61
Tympanogen	50,000.00	2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses:	50,000.00	2,270,000.00	\$ 669,399.61
Tympanogen <u>Return on Prior Investments, including gains and losses:</u> 418 Intelligence ArchMedx ArchMedx	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77	2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx Blue Triangle Ringobon Normshield	50,000.00 \$ 2,939,399.61 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/lgnite Steel Mountain DexComm/TypeZero	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15	\$ 2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 1,50,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12	2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge Eventbrite	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge Eventbrite Eventbrite	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 1,50,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72)	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge Eventbrite	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge Eventbrite Eventbrite Eventbrite	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92)	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/lgnite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 1,50,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16)	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/lgnite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge Eventbrite Ev	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10	\$ 2,270,000.00	\$ 669,399.61
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge ClearEdge Eventbrite Eve	50,000.00 \$ 2,939,399.61 5 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 1,50,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10 14,905.26 (15.00) 1,586.32	\$ 2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge ClearEdge Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Nexvortex Triblio Inc bank fees M37 EP Cyberalgorithms Canvas Sol (Acquiom)	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 1,50,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10 14,905.26 (15.00) 1,586.32 6,284.41	2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge ClearEdge Eventbrite Eve	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10 14,905.26 (15.00) 1,586.32 6,284.41 5,186.74	2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge ClearEdge Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Nexvortex Triblio Inc bank fees M37 EP Cyberalgorithms Canvas Sol (Acquiom)	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 1,50,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10 14,905.26 (15.00) 1,586.32 6,284.41	2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge ClearEdge Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Nexvortex Triblo Inc bank fees M37 EP Cyberalgorithms Canvas Sol (Acquiom)	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10 14,905.26 (15.00) 1,586.32 6,284.41 5,186.74	2,270,000.00	<u>\$ 669,399.61</u>
Tympanogen Return on Prior Investments, including gains and losses: 418 Intelligence ArchMedx ArchMedx Blue Triangle Ringobon Normshield Canvas Ohmygov/Ignite Steel Mountain DexComm/TypeZero Sophos/Invincea ClearEdge ClearEdge ClearEdge Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Eventbrite Nexvortex Triblio Inc bank fees M37 EP Cyberalgorithms Canvas Sol (Acquiom)	50,000.00 \$ 2,939,399.61 \$ 18,684.45 30,678.08 13,328.77 13,106.85 5,000.00 150,000.00 1,310,260.27 55,667.88 17,383.24 183,240.46 129,051.15 9,487.12 70,340.68 20,602.40 (356.72) (6,289.92) (2,162.16) 1,652.10 14,905.26 (15.00) 1,586.32 6,284.41 5,186.74	2,270,000.00	<u>\$ 669,399.61</u>

Center for Innovative Technology

FY2019	CRCF	Award	Detail

FY2019 CRCF Award Detail		Project Start	Project End	
Organization Name	CRCF Project Title	Date	Date	Award Amount
AgroSpheres	AgroSpheres Enhanced Delivery of Active Ingredients	06/17/2019	04/17/2020	\$50,000
Alexander BioDiscoveries	Small Molecule Inhibitors of the Influenza Virus Nucleoprotein for Drug Development	06/17/2019	12/16/2019	\$50,000
Amruta Inc	Self-Learning System for e-Discovery, among Large Text Corpus Data Sets to Improve Compliance, Forensics, and Customer Service, Using Machine Learning	06/17/2019	12/16/2019	\$50,000
BEAM Diagnostics, Inc	Using Behavioral Economics to Identify Best-Fit Personality Profiles Among Employment-Seeking Individuals	06/17/2019	12/31/2019	\$29,750
Commonwealth Center for Advanced Manufacturing	Additive Manufacturing of Metal Alloys for 3D Medical Devices	07/01/2019	06/30/2021	\$99,988
Commonwealth Center for Advanced Manufacturing	Advanced Analytics Framework for Deploying Automated Defect Detection in Manufacturing	07/01/2019	06/30/2020	\$98,166
Covenant Therapeutics, LLC	Drug Discovery for Gram-negative Rod Bacterial Infection	07/01/2019	06/30/2020	\$49,995
Eksdyne Inc.	Integrated System for Evolving Developing Devices	06/17/2019	06/16/2020	\$49,936
Embody LLC	Additive Manufacturing of Collagen Microfibers as an Internal Brace for Regenerating Ligaments of the Knee	06/17/2019	06/17/2020	\$50,000
Fend Incorporated	Low-Cost Data Diodes for Physical Protection of Connected Infrastructure	06/17/2019	12/17/2019	\$50,000
G2 Ops Global, Inc.	A Model-Based Framework for Quantifying Information Risk	07/01/2019	03/31/2020	\$42,984
George Mason University	Wearable Ultrasound System for Robust Sensing of Muscle Activation	06/17/2019	01/16/2021	\$98,456
Gradient Consulting	Achieving Eternal Flight with a Tethered Uni-Rotor Network (TURN) System	06/17/2019	09/09/2019	\$50,000
ICBiome	A Cloud-Based WGS Platform for Routine Surveillance of Hospital Pathogens	06/17/2019	12/16/2019	\$50,000
JKM Technologies, LLC	Local Footwear Manufacturing Using a Novel Cost-Effective Pellet-Based 3D Printing Process	07/01/2019	06/30/2020	\$50,000
Micro Harmonics Corporation	Commercialization of Cryogenic Millimeter-Wave Isolators	06/17/2019	12/17/2019	\$50,000
MOVA Technologies, Inc.	Panel-Bed Filter Proof-of-Concept Testing	07/01/2019	03/10/2020	\$50,000
NIRSleep Inc	Home Sleep Monitoring with a Compact and Inexpensive Wearable Neuro-Imaging Device	08/01/2019	07/31/2020	\$50,000
NOVI LLC	Next Generation, Intelligent, and Autonomous Satellites for an Emerging New Space Industry	06/17/2019	12/16/2019	\$48,700
Overa, Inc.	Development of a Non-hormonal Female Contraceptive Using an Egg-specific Antibody-drug Conjugate	06/17/2019	06/16/2020	\$50,000
	Peptide Inhibitor of Complement C1 (PIC1) as a Treatment for			
ReAlta Life Sciences	Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus	06/17/2019	06/16/2020	\$50,000
Responsible Robotics Corporation	A Robotics Monitoring and Control Platform	07/01/2019	12/31/2019	\$49,625
Ryzing Technologies	Braided Inflatable Robotic Technology (BIRT) for Dexterous Maritime Manipulation System (D2MS)	06/17/2019	06/30/2020	\$49,953
SeeHear LLC	Commercialization of an NIH- and NSF-Supported Web-Based Speech Perception Training System for Adults with Hearing Loss	07/01/2019	06/30/2020	\$50,000
Sentinel Robotic Solutions, LLC	Mobile Sentinel – Mobile Unmanned Automated Traffic Control Sensor and Gate System	06/17/2019	01/31/2020	\$25,000
Southeastern Universities Research Association	Development of High Resolution Radiotherapy Beam Characterization Technology Using Micropattern Gas Detection	08/01/2019	07/31/2020	\$100,000
Status Identity, Inc.	Continuous Authentication and Identification by Distinctive Characteristics	07/01/2019	02/28/2020	\$25,000

Organization Name	CRCF Project Title	Project Start Date	Project End Date	Award Amount
University of Virginia	VADstent to Prevent Cavity Collapse and Adverse Cardiac Remodeling	06/17/2019	06/30/2020	\$54,578
University of Virginia	Designer Enzymes as Green Alternatives to Protect High- Value Agricultural Products Pre- and Post-Harvest from Microbial Infection	07/01/2019	06/30/2020	\$100,000
Virginia Commonwealth University	Development of a Highly Efficient Air Filter for Inactivation of Airborne Germs	07/01/2019	06/30/2020	\$100,000
Virginia Commonwealth University	Rapid Cell Typing Technology for Forensic DNA Casework	06/24/2019	06/24/2020	\$100,000
/irginia Commonwealth University	Sulfated Glycosaminoglycans as Disease Biomarkes and Molecular Targets for Precision Medicine in Cancer	06/17/2019	06/16/2020	\$100,000
/irginia Commonwealth University	A Nanotechnology Approach for Streamlining Detection of Prognostic Translocations in Multiple Myeloma (MM)	07/01/2019	06/30/2020	\$100,000
/irginia Institute of Marine Science	Leveraging Deep Lens Technology to form a Video Inundation Monitoring System for StormSense	07/01/2019	06/30/2021	\$49,612
/irginia Tech	Development of a Connected Smart Vest for Improved Roadside Work Zone Safety	07/01/2019	06/30/2020	\$91,069
/irginia Tech	Precision Medicine Exosomal Drug Delivery Medtech for Heart Attack	06/17/2019	12/16/2020	\$100,000
/irongy LLC	Commercialization of Infectin	06/17/2019	06/16/2020	\$48,791
oltMed Inc.	Testing of an MRI-Compatible Electrode for Treating Brain Tumors with Non-Thermal Ablation	06/17/2019	12/16/2019	\$50,000
WynnVision LLC	Antimicrobial and Biocompatible Endotracheal Tubes	07/01/2019	06/30/2020	\$50,000

Item 126.10.D.2.c

Fiscal Year 2019 Quarter 4 June 30, 2019

Financial & Programmatic

M37 Equity Pool, LLC and M37 Carried Interest, LLC

M37 Equity Pool, LLC

Financial Report Unaudited

As of and for the years ended June 30, 2019 and 2018

M37 Equity Pool, LLC STATEMENT OF ASSETS, LIABILITIES and MEMBERS' CAPITAL

As of June 30, 2019 and 2018

	Unaudited 6/30/2019	Audited 6/30/2018	Change
ASSETS			
Current assets:			
Cash and cash equivalents	\$ -	\$ 5,095	\$ (5,095)
Total current assets		5,095	(5,095)
Total assets	-	5,095	(5,095)
LIABILITIES			
Current liabilities: Due to CIT		5,095	(5,095)
Total current liabilities		5,095	(5,095)
Total liabilities	-	5,095	(5,095)
MEMBERS' CAPITAL CIT			
Minority Members			
Total members' capital			<u> </u>
Total liabilities and members' capital	\$-	\$ 5,095	\$ (5,095)

M37 Equity Pool, LLC STATEMENT OF OPERATIONS and CHANGES IN MEMBERS' CAPITAL

For the year ended June 30, 2019 and 2018

	Unaudited 6/30/2019		Audited 6/30/2018		Change
REVENUES Net realized investment gain (loss)	\$ 2,145	\$	2,145	\$	
Total operating revenue	2,145		2,145		-
EXPENSES Operating expenses	 15		90		(75)
Total expenses	 15		90	<u> </u>	(75)
NET LOSS	2,130		2,055		75
Members' capital, beginning	-		(60)		60
Members' contributions/(distributions)	 (2,130)		(1,995)		(135)
Members' capital, ending	\$ 	\$	-	\$	

M37 Carried Interest, LLC

Financial Report Unaudited

As of and for the years ended June 30, 2019 and 2018

M37 Carried Interest, LLC STATEMENT OF ASSETS, LIABILITIES and MEMBERS' CAPITAL

As of June 30, 2019 and 2018

		naudited 30/2019	Audited 30/2018	С	hange
ASSETS					
Current assets:					
Cash and cash equivalents	_\$	10,985	\$ 11,000	\$	(15)
Total current assets		10,985	 11,000		(15)
Total assets		10,985	 11,000		(15)
LIABILITIES Current liabilities: Due to CIT		10,985	 11,000		(15)
Total current liabilities		10,985	 11,000		(15)
Total liabilities		10,985	 11,000		(15)
MEMBERS' CAPITAL CIT		-	 -		_
Total members' capital			 		-
Total liabilities and members' capital	\$	10,985	\$ 11,000	\$	(15)

M37 Carried Interest, LLC STATEMENT OF OPERATIONS and CHANGES IN MEMBERS' CAPITAL

For the years ended Jun 30, 2019 and 2018

	Unaudited 6/30/2019		Audited 6/30/2018		Change	
REVENUES						
Net realized investment gain (loss)	\$	17,738	\$		\$	17,738
Total operating revenue		17,738		-		17,738
EXPENSES Operating expenses		15		-		15
Total expenses		15		-		15
NET INCOME (LOSS)		17,723		-		17,723
Members' capital, beginning				(4,615)		4,615
Members' capital contribution (distribution)	-	(17,723)		4,615	-	(22,338)
Members' capital, ending	\$		\$	-	\$	-